Current Report Filing (8-k)
December 15 2021 - 4:16PM
Edgar (US Regulatory)
0001799788
false
0001799788
2021-12-15
2021-12-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported) December 15, 2021
Greenwich
LifeSciences, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-39555
|
|
20-5473709
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.
R. S. Employer
Identification
No.)
|
3992
Bluebonnet Dr, Building 14
Stafford,
TX 77477
(Address
of principal executive offices, including ZIP code)
(832)
819-3232
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock, $0.001 par value
|
|
GLSI
|
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.07 Submission of Matters to a Vote of Security Holders
On
December 15, 2021, Greenwich LifeSciences, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual
Meeting”). A total of 10,540,382 shares of common stock, constituting a quorum, were represented in person or by valid proxies
at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth
in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on October 19, 2021 are as follows:
Proposal
1. All of the five (5) nominees for director were elected to serve until the 2022 Annual Meeting of Stockholders or until their respective
successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of
the votes to elect the five (5) directors was as follows:
Directors
|
|
For
|
|
|
Against
|
|
|
Abstain
|
|
|
Broker Non Vote
|
|
David McWilliams
|
|
|
9,368,038
|
|
|
|
0
|
|
|
|
603,421
|
|
|
|
568,923
|
|
Snehal S. Patel
|
|
|
9,866,004
|
|
|
|
0
|
|
|
|
105,455
|
|
|
|
568,923
|
|
Eric Rothe
|
|
|
9,385,674
|
|
|
|
0
|
|
|
|
585,785
|
|
|
|
568,923
|
|
F. Joseph Daugherty, M.D.
|
|
|
9,817,393
|
|
|
|
0
|
|
|
|
154,066
|
|
|
|
568,923
|
|
Kenneth Hallock
|
|
|
9,689,781
|
|
|
|
0
|
|
|
|
281,678
|
|
|
|
568,923
|
|
Proposal
2. The appointment of Malone Bailey, LLP as the Company’s independent registered public accounting firm for its fiscal year
ended December 31, 2021 was ratified and approved by the stockholders by the votes set forth in the table below:
For
|
|
|
Against
|
|
|
Abstain
|
|
|
Broker Non Vote
|
|
|
10,523,113
|
|
|
|
6,200
|
|
|
|
11,069
|
|
|
|
0
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Greenwich
LifeSciences, Inc.
|
|
|
|
Date:
December 15, 2021
|
By:
|
/s/
Snehal Patel
|
|
|
Snehal
Patel
|
|
|
Chief
Executive Officer
|
Greenwich LifeSciences (NASDAQ:GLSI)
Historical Stock Chart
From Apr 2024 to May 2024
Greenwich LifeSciences (NASDAQ:GLSI)
Historical Stock Chart
From May 2023 to May 2024